Recently, Suzhou Suncadia Biopharmaceuticals Co Ltd, a subsidiary of Chinese pharmaceutical conglomerate Hengrui Medicine, achieved another milestone in immunotherapy. Its self-developed Vunakizumab Injection received approval from the National Medical Products Administration (NMPA) of China for use in treating adult patients with active ankylosing spondylitis (AS) who respond inadequately to conventional therapies.
The IL-17A has been confirmed as a key driving factor for AS. As a humanized IgG1 anti-IL-17A monoclonal antibody, the Vunakizumab Injection demonstrates high affinity for IL-17A, selectively binding to and blocking its pathogenic pathway, thereby offering a precisely targeted therapy for AS.
The Vunakizumab Injection was approved for marketing for treatment of psoriasis in August 2024. The approved new application provides a much-needed therapeutic alternative for a broader patient population.
May 6, 2025
